logo

For the Inventor, By the Inventor

Tübingen, Germany

Curevac Ag


USPTO Granted Patents = 97

% Expired Patents = 19.6



Trademarks = 12

Forward Citations = 3,019

Loading Chart...
Loading Chart...

61 inventors (with patents filed for the assignee):

goldMedal Jochen Probst (29 out of 37 patents)

silverMedal Andreas Thess (25 out of 67 patents)

bronzeMedal Thomas Schlake (22 out of 33 patents)

4.  Karl-Josef Kallen (20 out of 29 patents)

5.  Mariola Fotin-Mleczek (19 out of 27 patents)

6.  Ingmar Hoerr (16 out of 21 patents)

7.  Benjamin Petsch (14 out of 46 patents)

8.  Thomas Kramps (12 out of 26 patents)

9.  Patrick Baumhof (12 out of 22 patents)

10.  Margit Schnee (11 out of 21 patents)

11.  Steve Pascolo (11 out of 24 patents)

12.  Florian Von Der Mülbe (10 out of 20 patents)

13.  Tilmann Roos (7 out of 20 patents)

14.  Benyamin Yazdan Panah (7 out of 16 patents)

15.  Thomas Ketterer (7 out of 25 patents)


Core Competencies:
mRNA
Vaccines
Nucleic Acids
RNA Therapeutics
Immunostimulation
Protein Expression
Vaccine Composition
Long-Chain RNA
Combination Vaccines
Antigen Presentation
RNA-Encoded Proteins
Adjuvants

97 patents:

1. 12528855 - KRAS VARIANT MRNA MOLECULES (2026-01-20),
2. 11534405 - Dry powder composition comprising long-chain RNA (2022-12-27),
3. 11478552 - Hybrid carriers for nucleic acid cargo (2022-10-25),
4. 11471525 - Coronavirus vaccine (2022-10-18),
5. 11464847 - Lassa virus vaccine (2022-10-11),
6. 11464836 - RNA for treatment or prophylaxis of a liver disease (2022-10-11),
7. 11458195 - Combination of vaccination and inhibition of the PD-1 pathway (2022-10-04),
8. 11458193 - Combination of vaccination and inhibition of MHC class I restricted antigen presentation (2022-10-04),
9. 11433027 - Dry powder composition comprising long-chain RNA (2022-09-06),
10. 11421038 - RNA-coded antibody (2022-08-23),
11. 11413346 - Rotavirus vaccines (2022-08-16),
12. 11384375 - Immobilized poly(n)polymerase (2022-07-12),
13. 11369694 - Rabies vaccine (2022-06-28),
14. 11369691 - Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions (2022-06-28),
15. 11345920 - Artificial nucleic acid molecules for improved protein expression (2022-05-31),
CureVac AG is a leading clinical-stage biopharmaceutical company dedicated to developing fully optimized mRNA-based vaccines and therapeutics for the prevention and treatment of infectious diseases and cancer. The company's proprietary messenger RNA (mRNA) technology platform allows for the development of personalized medicines, targeting a wide range of diseases, and has attracted collaborations with major pharmaceutical companies. CureVac is headquartered in Tübingen, Germany.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Curevac Ag
97 Patents

#3 in Tübingen

#605 in Germany

#7,969 in the World

Tübingen, DE
Tübingen, Germany

Curevac Ag

Forward Citations = 3,019

61 inventors:

goldMedal Jochen Probst (29 out of 37 patents)

silverMedal Andreas Thess (25 out of 67 patents)

bronzeMedal Thomas Schlake (22 out of 33 patents)

4.  Karl-Josef Kallen (20 out of 29 patents)

5.  Mariola Fotin-Mleczek (19 out of 27 patents)

Please report any incorrect information to [email protected]
Loading…